Business Services Industry

Biotech Companies Question FDA Regulation Proposals.(Knight Ridder/Tribune Business News)

Knight Ridder/Tribune Business News, January, 2001 by Rosenberg, Ronald

Jan. 31--Biotechnology companies planning to conduct gene therapy and animal-to-human transplants are questioning new regulations that require them to provide more details about their tests and immediate public notification of side effects.

The proposed regulations from the U.S. Food and Drug Administration are designed to balance patient advocates' call for more public disclosure of controversial gene therapy trials with biotech companies' desire to keeping data confidential for competitive reasons.

The FDA said the new rules will provide public access, through the Internet, to a gene therapy clinical trial's design and safety parameters but without confidential personal information about the participants.

In a gene therapy trial, where...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here